Abstract Categories

Deadline for Abstract Submission : by August 31, 2020
Extended: by September 6, 2020

KCA Annual Meeting 2020 cordially invites you to submit your abstracts. Submitters are asked to choose their preferred presentation type and abstract categories when using the submission system. Before making your selection, please scan the entire list for the most appropriate abstract category.
Abstracts submitted by March 31, 2020 will remain valid and be automatically transferred to the online conference.





• Leukemia, Myelodysplasia, and Transplantation • Metabolism and Cancer
• Lymphoma and Plasma Cell Disorders • Oncogenomics 
• Head and Neck Cancer • Bioinformatics and Computational Molecular Biology
• Lung Cancer • Innovative Technologies in Cancer Research
• Gastrointestinal (Colorectal) Cancer • microRNAs and Other Noncoding RNAs
• Anal Cancer • Cancer Systems Biology
• Colorectal Cancer • Cellular Stress Responses
• Small Bowel Cancer • Cell Culture and Animal Models of Cancer
• Gastrointestinal (Noncolorectal) Cancer • Stem Cell Biology/Cancer Stem Cells/Developmental Oncobiology
• Esophageal or Gastric Cancer • Tumor Adhesion
• Hepatobiliary Cancer • Tumor Invasion and metastasis
• Pancreatic Cancer • Angiogenesis, Vasculogenesis, Microcirculation, and Cellular Microenvironment
• Neuroendocrine/Carcinoid • Tumor Microenvironment
• Other GI Cancer • In Vivo Imaging
• Breast Cancer • Radiation Biology
• Genitourinary Cancer • Carcinogenesis - Chemical, Viral, and Radiation
• Gynecologic Cancer • Drug Discovery and Design
• Sarcoma • Structural and Chemical Biology
• Neuroendocrine tumor • Proteomics, Metabolomics, and Biological Mass Spectrometry
• Melanoma/Skin Cancers • Chemical Aspects of Carcinogenesis
• Radiation Oncology • Imaging Agents and Radiotherapeutics
• Geriatric Oncology • Drug Delivery
• Pediatric Oncology • Translational Research Molecular Biology in the Clinic
• Supportive Care and Survivorship Research • Biostatistics in Clinical Trials
• Developmental Therapeutics • Molecular Biomarkers for Diagnosis, Prognosis, and Prediction
• Patient and Survivor Care • Clinical Immunology/Biological Therapy
• Cancer Prevention/Epidemiology • Experimental and Molecular Therapeutics
• Clinical Trials • Regulatory Science and Policy
• Ethics in Clinical Trials • New Molecular Targets
• Health Services Research • Mechanisms of Drug Action
• Cell Growth Signaling Pathways • Pharmacology, Pharmacogenetics, and Pharmacogenomics
• Cell Death • Drug Resistance
• Molecular Genetics • Biological Therapeutic Agents
• Oncogenes and Tumor Suppressor Genes • Small Molecule Therapeutic Agents
• Gene Regulation and Transcription Factors • Tumor Immunobiology
• Epigenetics • Gene and Vector-Based Therapy
• Cell Cycle • Prevention Research
• DNA Damage and Repair • Cancer Immunotherapy, Preclinical and Clinical